Investor mix
23 investors on record; lead investors include Investor Growth Capital, AGTC Funds; 3 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 12 | 52% |
| Private equity | 1 | 4% |
| Other / undisclosed | 10 | 43% |
Monoclonal antibodies against cancer, inflammatory and infectious diseases.
23 investors on record; lead investors include Investor Growth Capital, AGTC Funds; 3 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 12 | 52% |
| Private equity | 1 | 4% |
| Other / undisclosed | 10 | 43% |